- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT02403869
Quality of Life in Metastatic Breast Cancer (MBC) Patients in Second Line Monochemotherapy (DD-CMM)
Study of Quality of Life in Patients With Metastatic Breast Cancer Treated With Second-line Monochemotherapy
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
Post-authorization, prospective, multi-centre study in Metastatic Breast Cancer patients treated with second-line monochemotherapy.
A total of 200 patients are expected to be recruited from 32 Spanish sites.
In this study the results perceived by patients will be compiled to assess overall Quality of Life (QoL) in MBC patients treated with second-line monochemotherapy, using the EORTC QLQ-C30 questionnaire (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire) and its modules EORTC QLQ-BR23 (EORTC Breast Cancer specific) and EORTC QLQ-CIPN20 (EORTC Chemotherapy-Induced Peripheral Neuropathy).
Patients will be evaluated at the time of acceptance to participate in the study after signing the informed consent and will be tracked every three months during treatment with second-line monochemotherapy, coinciding with routine assessments within normal clinical practice. When the patient completes treatment with second-line chemotherapy he/she will enter the post-treatment period, with follow-up at six and 12 months after completion of treatment. Also, patients will be followed to assess survival until the end of the study (30 months after enrolment of the last patient in the study). Follow-up time has been established based on the median survival of patients with MBC
Studietyp
Inskrivning (Faktisk)
Kontakter och platser
Studieorter
-
-
-
Madrid, Spanien, 28034
- Hospital Universitario Ramon y Cajal
-
Madrid, Spanien, 28007
- Hospital Universitario Gregorio Maranon
-
Madrid, Spanien, 28702
- Hospital Infanta Sofia
-
-
Andalucía
-
Huelva, Andalucía, Spanien, 21005
- Hospital Juan Ramón Jiménez
-
Sevilla, Andalucía, Spanien, 41013
- Hospital Virgen del Rocío
-
Sevilla, Andalucía, Spanien, 41013
- Hospital Virgen de Valme
-
-
Aragón
-
Zaragoza, Aragón, Spanien, 50009
- Hospital Miguel Servet
-
Zaragoza, Aragón, Spanien, 50009
- Hospital Universitario Lozano Blesa
-
-
Baleares
-
Palma Mallorca, Baleares, Spanien, 07120
- Hospital Universitario Son Espases
-
Palma de Mallorca, Baleares, Spanien, 07198
- Hospital Son Llatzer
-
-
Canarias
-
La Laguna, Santa Cruz De Tenerife, Canarias, Spanien, 38320
- Hospital Universitario Canarias
-
-
Castilla La Mancha
-
Toledo, Castilla La Mancha, Spanien, 45071
- Hospital Virgen de la Salud. Toledo
-
-
Castilla Y León
-
Burgos, Castilla Y León, Spanien, 09005
- Hospital Universitario Burgos
-
León, Castilla Y León, Spanien, 24001
- Complejo Hospitalario de León
-
León, Castilla Y León, Spanien, 24404
- Hospital Bierzo
-
Salamanca, Castilla Y León, Spanien, 37007
- Hospital Universitario Salamanca
-
-
Cataluña
-
Barcelona, Cataluña, Spanien, 08022
- Centro Médico Teknon
-
Barcelona, Cataluña, Spanien, 08036
- Hospital Clinic Barcelona
-
Reus, Tarragona, Cataluña, Spanien, 43204
- Hospital Universitario San Joan de Reus
-
Sabadell, Cataluña, Spanien, 08208
- Corporación Sanitaria Parc Taulí- Sabadell
-
-
Comunidad Valenciana
-
Elche, Comunidad Valenciana, Spanien, 03203
- Hospital Universitario Elche
-
Valencia, Comunidad Valenciana, Spanien, 46026:
- Hospital Universitario y Politécnico La Fe
-
-
Extremadura
-
Badajoz, Extremadura, Spanien, 06080
- H. Infanta Cristina de Badajoz
-
Cáceres, Extremadura, Spanien, 10003
- H. San Pedro de Alcántara
-
-
Galicia
-
Ourense, Galicia, Spanien, 32005
- Complejo Hospitalario de Ourense
-
Pontevedra, Galicia, Spanien, 36071
- Complejo Hospitalario de Pontevedra-Montecelo
-
Santiago de Compostela, Galicia, Spanien, 15706
- Complejo Hospitalario Universitario de Santiago Compostela
-
Vigo, Galicia, Spanien, 36036
- Complejo Hospitalario de Vigo
-
-
Navarra
-
Pamplona, Navarra, Spanien, 31008
- Hospital Universitario de Navarra
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Testmetod
Studera befolkning
Beskrivning
Inclusion Criteria:
- Patients who give their written informed consent.
- Patients with metastatic breast cancer who start treatment with second-line monochemotherapy.
- Patients of both sexes, at least 18 years of age and of any race.
- Patients with life expectancy longer than or equal to 12 weeks.
- Patients with histological or cytological diagnosis of Her-2/neu negative breast adenocarcinoma.
- Patients with ability enough to understand the questionnaires.
Exclusion Criteria:
- Pregnant or lactating women.
- Patients who have been treated with chemotherapy in the last three weeks
- Patients who refuse to participate in the study.
Studieplan
Hur är studien utformad?
Designdetaljer
Kohorter och interventioner
Grupp / Kohort |
---|
Group 1
MBC patients starting treatment with monochemotherapy for second line of quimiotherapy treatment for metastatic disease
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Definitive deterioration at 6 months
Tidsram: 6 months
|
Proportion of patients with definitive deterioration at six months after initiation of second-line mono-chemotherapy for MBC
|
6 months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
Definitive deterioration at 3 months
Tidsram: 3 Months
|
Description Proportion of patients with definitive deterioration at 3 months after the start of the second-line mono-chemotherapy and at the time of disease progression or completion of treatment for other reasons
|
3 Months
|
Definitive deterioration at 9 months
Tidsram: 9 Months
|
Proportion of patients with definitive deterioration at 9 months after the start of the second-line mono-chemotherapy and at the time of disease progression or completion of treatment for other reasons
|
9 Months
|
Definitive deterioration at 12 months
Tidsram: 12 Months
|
Proportion of patients with definitive deterioration at 12 months after the start of the second-line mono-chemotherapy and at the time of disease progression or completion of treatment for other reasons
|
12 Months
|
Time to Definitive deterioration (TTDD)
Tidsram: Up to 42 months
|
Estimated median TTDD using the actuarial method
|
Up to 42 months
|
Overall survival
Tidsram: Up to 42 months
|
Estimated overall survival using the Kaplan-Meier method
|
Up to 42 months
|
TTDD as a prognostic factor
Tidsram: Up to 42 months
|
Determine if TTDD is an independent prognostic factor for overall survival using Cox regression.
|
Up to 42 months
|
Quality of life
Tidsram: Up to 42 months
|
Comparison of the mean score of the scales of the EORTC QLQ-C30, EORTC QLQ-BR23 and between patients ≥70 years and <70 years at baseline, every 3 months approximately and at the time of disease progression or completion of treatment for other reasons
|
Up to 42 months
|
Quality of life every 3 months
Tidsram: Up to 42 months
|
Score in the scales of the EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires at baseline, every 3 months approximately and at the time of disease progression or completion of treatment for other reasons.
|
Up to 42 months
|
Chemotherapy-induced peripheral neuropathy
Tidsram: Up to 42 months
|
Incidence, management and duration of chemotherapy-induced peripheral neuropathy at baseline, every 3 months approximately up to disease progression and at 6 and 12 months after completion of second-line chemotherapy
|
Up to 42 months
|
Chemotherapy-induced peripheral neuropathy in the EORTC QLQ-CIPN20
Tidsram: Up to 42 months
|
Assess the effect of chemotherapy-induced peripheral neuropathy in the EORTC QLQ-CIPN20 quality of life questionnaire at baseline, every 3 months approximately up to disease progression or completion of treatment for other reasons and at 6 and 12 months after completion of second-line chemotherapy
|
Up to 42 months
|
Definitive deterioration
Tidsram: Up to 42 months
|
Comparison of the proportion of patients with definitive deterioration at every 3 months approximately up to disease progression or completion of treatment for other reasons in patients with ECOG 0-1 and ECOG 2-3, using the chi-squared test.
|
Up to 42 months
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Faktisk)
Avslutad studie (Faktisk)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Uppskatta)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- CEL-CMM-2013-01
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på Bröstneoplasmer
-
Tianjin Medical University Cancer Institute and...Guangxi Medical University; Sun Yat-sen University; Chinese PLA General Hospital och andra samarbetspartnersAvslutadDen kliniska tillämpningsguiden för Conebeam Breast CTKina
-
ETOP IBCSG Partners FoundationAvslutadBreast Cancer Invasive NosItalien
-
Spanish Breast Cancer Research GroupHoffmann-La Roche; Roche Farma, S.AAvslutadBreast Cancer Invasive NosSpanien
-
University Health Network, TorontoAvslutadBreast Cancer Invasive Nos | Primär invasiv bröstcancerKanada
-
Novartis PharmaceuticalsAvslutadMetastaserad bröstcancer (MBC) | Locally Advance Breast Cancer (LABC)Storbritannien, Spanien
-
Pomeranian Medical University SzczecinMaria Sklodowska-Curie National Research Institute of Oncology; Regional...OkändBRCA1-mutation | Breast Cancer Invasive NosPolen
-
Wake Forest University Health SciencesNational Cancer Institute (NCI)AvslutadMetastatisk malign neoplasm | Ooperbar malign neoplasm | Avancerad malign neoplasmFörenta staterna
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, inte rekryterandeMalign neoplasm | Metastatisk malign neoplasm | Avancerad malign neoplasm | Återkommande malign neoplasm | Lokalt avancerad malign neoplasmFörenta staterna
-
McMaster UniversityCanadian Breast Cancer FoundationAvslutadBreast Cancer Invasive Nos | Steg 0 BröstkarcinomKanada
-
Massachusetts General HospitalRekryteringMalign neoplasm | Benign neoplasmFörenta staterna